What was GILEAD SCIENCES, INC.'s revenue in Q2 2026?

GILEAD SCIENCES, INC. reported revenue of $7.8B (+10.2% year-over-year) for Q2 2026.

What was GILEAD SCIENCES, INC.'s EPS in Q2 2026?

GILEAD SCIENCES, INC. reported diluted EPS of $-8.45 (-641.7% year-over-year) for Q2 2026.

What is GILEAD SCIENCES, INC.'s guidance for fy_full?

GILEAD SCIENCES, INC. provided fy_full guidance of $30.1B to $30.4B.

GILEAD SCIENCES, INC. (GILD) Earnings - Revenue, EPS & Net Income

8 quarters held5/6 transcripts analyzed2/40 figures attested

Connect your agent

PeriodRevenueYoYNet incomeEPS (dil.)Filed

Q2 2026$7.8B+10.2%$-10.5B$-8.45Aug 4, 2026

LATESTEarnings filing (8-K)10-QFiled Aug 4, 2026, 4:03 PM ET

Earnings call · Aug 4, 2026transcript View original prepared remarks Q&A deck webcast

	Q2 FY26	YoY
Revenue	$7.8B¹	+10.2%
Net income	$-10.5B	-635.5%
Op income	$-10.4B	-520.1%
EPS (dil.)	$-8.45	-641.7%
EPS (basic)	$-8.45	-639.5%
Gross margin	79.3%	+0.6pp
Op margin	-133.2%	-168.1pp
Net margin	-134.5%	-162.2pp

[1] “Total revenues 7,803” view source

Guidance & outlook

Management guidance

Q2 2026

fy_full

revenue

$30.1B—$30.4B

other

29.8B—30.1B

other

300M—300M

eps_diluted

$-3.75—$-3.40

eps_diluted

$-0.65—$-0.30

Call guidance

Q2 2026

Metric	Value	Period	Specificity	vs Prior
hiv_growth	9% to 10%	FY2026	tight_range	Raised
hiv_sales	9% and 10%	FY2026	tight_range	New
yestugo_sales	approximately $1 billion	FY2026	point	New
base_business_sales	$29.8 and $30.1 billion	FY2026	tight_range	Raised
total_product_sales	$30.1 and $30.4 billion	FY2026	tight_range	Raised
non_gap_diluted_eps	$8.50 to $8.85	FY2026	tight_range	New
hiv_sales	9% to 10%	FY2026	tight_range	New
yestugo_sales	approximately $1 billion	FY2026	point	New
cell_therapy_sales	mid-teens percentage	FY2026	directional	New
biktari_sales	$300 million	FY2026	point	New
acquired_iprd	$11.5 billion	FY2026	point	New
effective_tax_rate	140 and 115%	FY2026	wide_range	Raised
non_gap_diluted_eps	negative 65 cents and negative 30 cents	FY2026	wide_range	New
non_gap_diluted_eps	$8.50 to $8.85	FY2026	tight_range	New
yestugo_sales	approximately $1 billion	FY2026	point	New
hiv_sales	9% to 10%	FY2026	tight_range	New
base_business_sales	6% to 7%	FY2026	tight_range	Lowered
total_product_sales	$30.1 and $30.4 billion	FY2026	tight_range	Raised
non_gap_diluted_eps	$8.50 to $8.85	FY2026	tight_range	New
non_gap_diluted_eps	negative 65 cents and negative 30 cents	FY2026	wide_range	New
effective_tax_rate	140 and 115%	FY2026	wide_range	Raised
acquired_iprd	$11.5 billion	FY2026	point	New
hiv_sales	9% to 10%	FY2026	tight_range	New
yestugo_sales	approximately $1 billion	FY2026	point	New
base_business_sales	$29.8 and $30.1 billion	FY2026	tight_range	Raised
total_product_sales	$30.1 and $30.4 billion	FY2026	tight_range	Raised
non_gap_diluted_eps	$8.50 to $8.85	FY2026	tight_range	New
non_gap_diluted_eps	negative 65 cents and negative 30 cents	FY2026	wide_range	New
effective_tax_rate	140 and 115%	FY2026	wide_range	Raised
acquired_iprd	$11.5 billion	FY2026	point	New
hiv_sales	9% to 10%	FY2026	tight_range	New
yestugo_sales	approximately $1 billion	FY2026	point	New
base_business_sales	6% to 7%	FY2026	tight_range	Lowered
total_product_sales	$30.1 and $30.4 billion	FY2026	tight_range	Raised
non_gap_diluted_eps	$8.50 to $8.85	FY2026	tight_range	New
non_gap_diluted_eps	negative 65 cents and negative 30 cents	FY2026	wide_range	New
effective_tax_rate	140 and 115%	FY2026	wide_range	Raised
acquired_iprd	$11.5 billion	FY2026	point	New
hiv_sales	9% to 10%	FY2026	tight_range	New
yestugo_sales	approximately $1 billion	FY2026	point	New
base_business_sales	$29.8 and $30.1 billion	FY2026	tight_range	Raised
total_product_sales	$30.1 and $30.4 billion	FY2026	tight_range	Raised
non_gap_diluted_eps	$8.50 to $8.85	FY2026	tight_range	New
non_gap_diluted_eps	negative 65 cents and negative 30 cents	FY2026	wide_range	New
effective_tax_rate	140 and 115%	FY2026	wide_range	Raised
acquired_iprd	$11.5 billion	FY2026	point	New

Special items & operational metrics

Operational metrics

Q2 2026

Biktarvy

3800.0M

+7.4% YoY

Prior year: 3530.0M

dollars

Descovy

967.0M

+48.1% YoY

Prior year: 653.0M

dollars

Livdelzi

167.0M

+114.1% YoY

Prior year: 78.0M

dollars

Tecartus

70.0M

-23.9% YoY

Prior year: 92.0M

dollars

Trodelvy

457.0M

+25.6% YoY

Prior year: 364.0M

dollars

Veklury

23.0M

-81.0% YoY

Prior year: 121.0M

dollars

Yescarta

346.0M

-12.0% YoY

Prior year: 393.0M

dollars

Q1 2026$7.0B+4.4%$2.0B$1.61May 7, 2026

Earnings filing (8-K)10-QFiled May 7, 2026, 4:03 PM ET

Earnings call · May 7, 2026transcript View original prepared remarks Q&A deck webcast

	Q1 FY26	YoY
Revenue	$7.0B¹	+4.4%
Net income	$2.0B	+53.7%
Op income	$2.6B	+15.6%
EPS (dil.)	$1.61	+54.8%
EPS (basic)	$1.63	+53.8%
Gross margin	79.2%	+2.5pp
Op margin	37.2%	+3.6pp
Net margin	29.0%	+9.3pp

[1] “Total revenues 6,960” view source

Q4 2025$7.9B+4.7%$2.2B$1.74Feb 10, 2026

Earnings filing (8-K)10-KFiled Feb 10, 2026, 4:02 PM ET

Earnings call · Feb 10, 2026transcript View original prepared remarks Q&A deck webcast

	Q4 FY25	YoY	FY25
Revenue	$7.9B	+4.7%	$29.4B
Net income	$2.2B	+22.4%	$8.5B
Op income	$2.0B	-19.1%	$10.0B
EPS (dil.)	$1.74	+22.5%	–
EPS (basic)	$1.76	+23.1%	–
Gross margin	79.5%	+0.5pp
Op margin	25.0%	-7.4pp
Net margin	27.6%	+4.0pp

Q3 2025$7.8B+3.0%$3.1B$2.43Oct 30, 2025

Earnings filing (8-K)10-QFiled Oct 30, 2025, 4:04 PM ET

Earnings call · Oct 30, 2025transcript View original prepared remarks Q&A deck webcast

	Q3 FY25	YoY	9M FY25
Revenue	$7.8B	+3.0%	$21.5B
Net income	$3.1B	+143.6%	$6.3B
Op income	$3.3B	+274.3%	$8.0B
EPS (dil.)	$2.43	+143.0%	$5.04
EPS (basic)	$2.46	+146.0%	$5.08
Gross margin	78.6%	-0.5pp
Op margin	42.8%	+31.0pp
Net margin	39.3%	+22.7pp

Q2 2025$7.1B+1.8%$2.0B$1.56Aug 7, 2025

Earnings filing (8-K)10-QFiled Aug 7, 2025, 4:26 PM ET

Earnings call · Aug 7, 2025transcript View original prepared remarks Q&A deck webcast

	Q2 FY25	YoY	6M FY25
Revenue	$7.1B	+1.8%	$13.7B
Net income	$2.0B	+21.4%	$3.3B
Op income	$2.5B	-6.4%	$4.7B
EPS (dil.)	$1.56	+20.9%	$2.61
EPS (basic)	$1.57	+21.7%	$2.63
Gross margin	78.7%	+1.0pp
Op margin	34.9%	-3.1pp
Net margin	27.7%	+4.5pp

Q1 2025––––Apr 24, 2025

10-QFiled Apr 24, 2025, 4:03 PM ET

Earnings calldeck webcast

	Q1 FY25	YoY
Revenue	–	–
Net income	–	–
Op income	–	–
EPS (dil.)	–	–
EPS (basic)	–	–

Q4 2024––––Feb 11, 2025

10-KFiled Feb 11, 2025, 4:04 PM ET

Earnings call · Feb 11, 2025deck webcast

	Q4 FY24	YoY
Revenue	–	–
Net income	–	–
Op income	–	–
EPS (dil.)	–	–
EPS (basic)	–	–

Q3 2024––––Nov 6, 2024

10-QFiled Nov 6, 2024, 4:09 PM ET

Earnings calldeck webcast

	Q3 FY24	YoY
Revenue	–	–
Net income	–	–
Op income	–	–
EPS (dil.)	–	–
EPS (basic)	–	–

Filing coverage

59 filings indexed · 69,931 XBRL facts

Filing	Date	Period	Sections	Tables
10-Q	2026-08-06	–	41	46
8-K	2026-08-04	Q2 2026	12	0
8-K	2026-05-20	–	3	0
8-K	2026-05-07	Q1 2026	11	0
10-Q	2026-05-07	–	40	52
8-K	2026-05-04	–	1	0
8-K	2026-04-28	–	2	0
DEF 14A	2026-03-20	–	24	0
10-K	2026-02-24	–	64	90
8-K	2026-02-23	–	3	0

Showing the latest 10 of 59 — the full set is in the API.

Related Research

Analysis

Guidance & outlook

Management guidance

fy_full

Call guidance

Special items & operational metrics

Operational metrics

Filing coverage

Related Research

The $1.7B Hidden Cost of Stryker's Acquisition Machine

Related Research

The $1.7B Hidden Cost of Stryker's Acquisition Machine

GILEAD SCIENCES, INC. (GILD) Earnings History

Guidance & outlook

Management guidance

fy_full

Call guidance

Special items & operational metrics

Operational metrics

Filing coverage

Related Research

The $1.7B Hidden Cost of Stryker's Acquisition Machine

Related Research

The $1.7B Hidden Cost of Stryker's Acquisition Machine